Is MRUS or JEPQ a better dividend investment in 2026?

MRUS currently yields 2.22% with a 5% 5-year dividend growth rate. JEPQ yields 11.10% with 5% growth. The better choice depends on your goal: JEPQ offers higher current income.

What is the dividend yield difference between MRUS and JEPQ?

MRUS has a forward dividend yield of 2.22% ($2.00/share annually). JEPQ yields 11.10% ($6.16/share annually). The yield gap is 8.88 percentage points.

Home › Compare › MRUS vs JEPQ

MRUS vs JEPQ: Dividend Comparison 2026

MRUS yields 2.22% · JEPQ yields 11.10%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 JEPQ wins by $21.8K in total portfolio value

INVESTMENT

TIME HORIZON10 years

MRUS

● Live price

2.22%

Share price

$90.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$23.0K

Annual income

$256.54

Full MRUS calculator →

JEPQ

JPMorgan Nasdaq Equity Premium Income ETF

● Live price

11.10%

Share price

$55.52

Annual div

$6.16

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$44.8K

Annual income

$2,152.59

Full JEPQ calculator →

Portfolio growth — MRUS vs JEPQ

📍 JEPQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	MRUS	JEPQ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, MRUS + JEPQ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

MRUS pays

JEPQ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MRUS

Annual income on $10K today (after 15% tax)

$188.89/yr

After 10yr DRIP, annual income (after tax)

$218.06/yr

JEPQ

Annual income on $10K today (after 15% tax)

$943.83/yr

After 10yr DRIP, annual income (after tax)

$1,829.70/yr

At 15% tax rate, JEPQ beats the other by $1,611.64/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MRUS + JEPQ for your $10,000?

MRUS: 50%JEPQ: 50%

100% JEPQ50/50100% MRUS

Portfolio after 10yr

$33.9K

Annual income

$1,204.56/yr

Blended yield

3.56%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRUS right now

MRUS

Analyst Ratings

Buy

Hold

Consensus: Hold

Price Target

$97.00

+7.8% upside vs current

Range: $97.00 — $97.00

Altman Z

34.5

Piotroski

3/9

JEPQ

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MRUS buys

JEPQ buys

No recent congressional trades found for MRUS or JEPQ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricMRUSJEPQ

Forward yield	2.22%	11.10% ✓
Annual dividend / share	$2.00	$6.16 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$23.0K	$44.8K ✓
Annual income after 10y	$256.54	$2,152.59 ✓
Total dividends collected	$2.4K	$16.3K ✓
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: MRUS vs JEPQ ($10,000, DRIP)

Year	MRUS Portfolio	MRUS Income/yr	JEPQ Portfolio	JEPQ Income/yr	Gap
1← crossover	$10,922	$222.22	$11,930	$1,110.39	$1.0K → JEPQ
2	$11,914	$226.84	$14,133	$1,224.34	$2.2K → JEPQ
3	$12,979	$231.24	$16,632	$1,340.46	$3.7K → JEPQ
4	$14,123	$235.43	$19,454	$1,457.97	$5.3K → JEPQ
5	$15,351	$239.43	$22,626	$1,576.08	$7.3K → JEPQ
6	$16,669	$243.22	$26,175	$1,694.09	$9.5K → JEPQ
7	$18,082	$246.82	$30,133	$1,811.32	$12.1K → JEPQ
8	$19,598	$250.24	$34,531	$1,927.17	$14.9K → JEPQ
9	$21,224	$253.47	$39,403	$2,041.08	$18.2K → JEPQ
10	$22,966	$256.54	$44,787	$2,152.59	$21.8K → JEPQ

MRUS vs JEPQ: Complete Analysis 2026

MRUS — Stock

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Full MRUS Calculator →

JEPQ — ETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →

📬

Get this MRUS vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MRUS vs SCHD MRUS vs JEPI MRUS vs O MRUS vs KO MRUS vs MAIN MRUS vs XYLD MRUS vs QYLD MRUS vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.